Seagen and Nurix Collaborate to Explore DACs as Potential ADC Alternatives
TL;DR Summary
Seagen has partnered with Nurix to develop degrader-antibody conjugates (DAC), combining their expertise in antibody-drug conjugates (ADCs) and protein degradation. Seagen will pay $60 million upfront, with the potential for $3.4 billion in milestones and future royalties for Nurix.
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
63%
106 → 39 words
Want the full story? Read the original article
Read on Endpoints News